Polpharma Group, a leading pharmaceutical company, urges the European Union to take decisive action to conclude the pharmaceutical reform and strengthen Europe’s capacity to produce essential medicines. We advocate for early access to generics to optimize health payer budgets and enable treatments for more patients. In the face of unprecedented geopolitical uncertainty, it is crucial to place public health at the center of all political decisions.